Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...
On Monday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $164.23 which represents a slight increase of $3.60 or 2.24% from the prior close of $160.63. The stock opened at $160.16 and ...
The Manufacturers Life Insurance Company lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 1.8% ...
Biogen Inc.’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai ...
Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...
On Friday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $160.51 which represents a slight increase of $0.68 or 0.43% from the prior close of $159.83. The stock opened at $160.72 and ...
Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
Bearish flow noted in Biogen (BIIB) with 1,136 puts trading, or 1.1x expected. Most active are Apr-25 160 puts and 11/29 weekly 162.5 calls, ...
A downtrend has been apparent in Biogen Inc. (BIIB ... year has led to an increase in the consensus EPS estimate by 1.7% over the last 30 days. And an upward trend in earnings estimate revisions ...
On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback